Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J; TAKO 05/ABCSG R-02 Trial Investigators. Ofner D, et al. Among authors: thaler j. Strahlenther Onkol. 2011 Feb;187(2):100-7. doi: 10.1007/s00066-010-2182-6. Epub 2011 Jan 21. Strahlenther Onkol. 2011. PMID: 21267531 Clinical Trial.
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG; Austrian Fulvestrant Registry. Bartsch R, et al. Among authors: thaler j. Breast Cancer Res Treat. 2009 May;115(2):373-80. doi: 10.1007/s10549-008-0132-0. Epub 2008 Jul 26. Breast Cancer Res Treat. 2009. PMID: 18661231 Clinical Trial.
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R; ABCSG-12 Trial Investigators; Marth C. Gnant M, et al. N Engl J Med. 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. N Engl J Med. 2009. PMID: 19213681 Free article. Clinical Trial.
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. Ludwig H, et al. Among authors: thaler j. J Clin Oncol. 2010 Oct 20;28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7. J Clin Oncol. 2010. PMID: 20823423 Clinical Trial.
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial.
Resch G, De Vries A, Öfner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group. Resch G, et al. Among authors: thaler j. Radiother Oncol. 2012 Jan;102(1):10-3. doi: 10.1016/j.radonc.2011.06.008. Epub 2011 Jul 7. Radiother Oncol. 2012. PMID: 21741716 Clinical Trial.
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Valent P, et al. Among authors: thaler j. Crit Rev Oncol Hematol. 2012 Jun;82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7. Crit Rev Oncol Hematol. 2012. PMID: 21903413 Review.
506 results